Amalgamated Financial’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Amalgamated Financial’s Portfolio CYT Stock Details CYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$5K	Buy	+1,232	New	+$7.01K	﹤0.01%	2964

Other funds holding CYT

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OMC

OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Amalgamated Financial's CYT Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Cyteir Therapeutics, Inc. Common Stock (CYT) in Q1 2022: 1,232 shares worth $5K. The stake represents ﹤0.01% of the portfolio and ranks #2964 among its holdings.

52 funds tracked by Wall St. Rank hold CYT as of Q1 2022.

Amalgamated Financial held 1,232 shares of Cyteir Therapeutics, Inc. Common Stock worth $5K as of Q1 2022.
Cyteir Therapeutics, Inc. Common Stock was a new Amalgamated Financial position in Q1 2022.
Cyteir Therapeutics, Inc. Common Stock made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2964 holding.
52 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.